Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China.
Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China.
EBioMedicine. 2018 Jun;32:134-141. doi: 10.1016/j.ebiom.2018.05.022. Epub 2018 Jun 13.
Current methods of lymph node (LN) staging are controversial in predicting the survival of SBA. We aimed to develop an alternative LN-classification-based nomogram to individualize SBA prognosis.
Based on the data from the Surveillance, Epidemiology, and End Results (SEER) database of patients diagnosed with SBA between 2004 and 2014, we identified the cut-off points for the number of LNs examined and the number found to be metastatic using the K-adaptive partitioning (KAPS) algorithm. Using metastatic LNs, a nomogram predicting the survival of SBA was derived, internally and externally validated, and measured by calibration curve, C-index, and decision curve analysis (DCA), and compared to the 8th TNM stage.
A total of 1516 patients were included. The cut-off of 17 was the optimal examined LN number. For metastatic LN numbers, the cut-off points were 0, 2, and 8. The C-index for the nomogram was higher than the 8th TNM staging (internal: 0.734; 95% CI, 0.693 to 0.775 vs. 0.677; 95% CI, 0.652 to 0.702, P < 0.001; external: 0.715; 95% CI, 0.674 to 0.756 vs. 0.648; 95% CI, 0.602 to 0.693, P < 0.001). Also, the nomogram showed good calibration in internal and external validation and larger net benefit than TNM staging.
We modified current N staging into a 4-level staging system based on the number of metastatic LNs: N0, no LN metastasis; N1, 1-2 metastatic LNs; N2, 3-8 metastatic LNs, and N3, >8 metastatic LNs and set the least examined LN number to 17. A nomogram based on this staging showed great clinical usability than TNM staging for predicting the survival of SBA patients.
目前的淋巴结(LN)分期方法在预测 SBA 患者的生存方面存在争议。我们旨在开发一种替代的基于淋巴结分类的列线图,以实现 SBA 预后的个体化。
基于 2004 年至 2014 年期间在 SEER 数据库中诊断为 SBA 的患者数据,我们使用 K 自适应分区(KAPS)算法确定了检查的淋巴结数量和发现的转移淋巴结数量的截断值。使用转移的淋巴结,我们得出了一个预测 SBA 患者生存的列线图,通过内部和外部验证,并通过校准曲线、C 指数和决策曲线分析(DCA)进行测量,并与第 8 版 TNM 分期进行比较。
共纳入 1516 例患者。检查的最佳 LN 数量为 17。对于转移的 LN 数量,截断值为 0、2 和 8。列线图的 C 指数高于第 8 版 TNM 分期(内部:0.734;95%CI,0.693 至 0.775 vs. 0.677;95%CI,0.652 至 0.702,P<0.001;外部:0.715;95%CI,0.674 至 0.756 vs. 0.648;95%CI,0.602 至 0.693,P<0.001)。此外,列线图在内部和外部验证中均显示出良好的校准度,并且比 TNM 分期具有更大的净获益。
我们基于转移的淋巴结数量将当前的 N 分期修改为 4 级分期系统:N0,无淋巴结转移;N1,1-2 个转移淋巴结;N2,3-8 个转移淋巴结,N3,>8 个转移淋巴结,并且设定检查的最少淋巴结数量为 17。基于该分期的列线图在预测 SBA 患者生存方面比 TNM 分期具有更好的临床实用性。